Heart failure after myocardial infarction
Conditions
Interventions
Experimental group:Conventional treatment+ Vericiguat 2.5-10mg qd
Control group:Conventional treatment
Sponsors
China-Japan Union Hospital of Jilin University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Written informed consent is obtained. 2. Aged >= 18 years. 3. Hospitalization for acute myocardial infarction (AMI). Definition of AMI: Acute myocardial injury [evidenced by a rise and/or fall of serum cardiac troponin values, with at least one value above the 99th percentile upper reference limit (URL)] with clinical evidence of acute myocardial ischemia. This evidence includes at least one of the following: (1) Symptoms of acute myocardial ischemia; (2) New ischemic electrocardiographic (ECG) changes; (3) Development of pathological Q waves; (4) Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality in a pattern consistent with ischemic etiology; (5) Identification of a coronary thrombus by angiography or intracoronary imaging. 4. Left ventricular ejection fraction (LVEF) <= 50% as assessed by echocardiography on admission. LVEF Assessment Method: LVEF is primarily evaluated using echocardiography. The reported LVEF value should be the average of three independent measurements. All echocardiographic assessments must be reviewed and confirmed by two cardiologists.
Exclusion criteria
Exclusion criteria: 1. Known hypersensitivity to vericiguat or any of its excipients. 2. Concurrent use of other soluble guanylate cyclase (sGC) stimulators (e.g., riociguat) or phosphodiesterase type 5 (PDE5) inhibitors (e.g., sildenafil). 3. Persistent systolic blood pressure (SBP) = 3 consecutive measurements, or the presence of symptomatic hypotension (e.g., dizziness, headache, fatigue, pallor, weakness). 4. Known history of chronic heart failure (HF) prior to the index event. 5. Presence of any non-cardiac condition (including active malignancy) expected to limit life expectancy to less than 12 months. 6. Severe renal impairment, defined as an estimated glomerular filtration rate (eGFR) 3 times the upper limit of normal (ULN). 8. Pregnancy, lactation, or planned pregnancy in the near future. 9. Inability or unwillingness to comply with follow-up procedures.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Whether the left ventricular ejection fraction (LVEF) increased by >= 10% (from baseline); | — |
Secondary
| Measure | Time frame |
|---|---|
| NT-proBNP;Cardiac death;Re-hospitalization for heart failure;All-cause mortality;left ventricular ejection fraction;left atrial diameter;left ventricular end-diastolic diameter;mitral regurgitation area; | — |
Countries
China
Contacts
Public ContactHe Yuquan
China-Japan Union Hospital of Jilin University
Outcome results
None listed